Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-Polycythaemia Vera”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02556931
What this trial is testing

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaSmall Lymphocytic Lymphoma+11 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 117
Testing effectiveness (Phase 2)Study completedNCT00509899
What this trial is testing

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Who this might be right for
MyelofibrosisPolycythemia VeraThrombocytosis
Incyte Corporation 154
Testing effectiveness (Phase 2)Study completedNCT02515630
What this trial is testing

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis
Sierra Oncology LLC - a GSK company 41
Large-scale testing (Phase 3)Active Not RecruitingNCT04717414
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Who this might be right for
Myeloproliferative DisordersMyelofibrosisPrimary Myelofibrosis+2 more
Celgene 313
Early research (Phase 1)WithdrawnNCT04896112
What this trial is testing

LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+2 more
Lynk Pharmaceuticals Co., Ltd
Large-scale testing (Phase 3)Ended earlyNCT01437787
What this trial is testing

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 289
Not applicableEnded earlyNCT00899951
What this trial is testing

Studying Fentanyl in Patients With Cancer

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+8 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2
Testing effectiveness (Phase 2)Study completedNCT01340651
What this trial is testing

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Who this might be right for
Myelofibrosis
Incyte Corporation 41
Testing effectiveness (Phase 2)UnknownNCT04485260
What this trial is testing

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
Myelofibrosis
Kartos Therapeutics, Inc. 36
Early research (Phase 1)Study completedNCT00080925
What this trial is testing

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+3 more
National Institutes of Health Clinical Center (CC) 20
Testing effectiveness (Phase 2)WithdrawnNCT01101412
What this trial is testing

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

Who this might be right for
Chronic Myeloproliferative DisordersInfectionLeukemia+6 more
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Active Not RecruitingNCT04603495
What this trial is testing

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Novartis Pharmaceuticals 430
Early research (Phase 1)Looking for participantsNCT07379125
What this trial is testing

Therapeutic RSK1 Targeting in Myelofibrosis

Who this might be right for
Myelofibrosis
Washington University School of Medicine 18
Testing effectiveness (Phase 2)Ended earlyNCT02226172
What this trial is testing

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Pfizer 21
Early research (Phase 1)Study completedNCT03895112
What this trial is testing

MPN-RC 118 AVID200 in Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis+2 more
John Mascarenhas 21
Testing effectiveness (Phase 2)Ended earlyNCT00931762
What this trial is testing

Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraPost-Essential Thrombocytopenia
Novartis Pharmaceuticals 35
Testing effectiveness (Phase 2)Looking for participantsNCT06517875
What this trial is testing

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Who this might be right for
Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline 68
Large-scale testing (Phase 3)Study completedNCT02101268
What this trial is testing

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sierra Oncology LLC - a GSK company 156
Early research (Phase 1)Ended earlyNCT03373877
What this trial is testing

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Samus Therapeutics, Inc. 4
Large-scale testing (Phase 3)Ended earlyNCT04551066
What this trial is testing

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 252
Next Page